Conrad Flick, MD
Family Medicine · Raleigh, NCNPI 1003949595
Payments from drug & device makers
Across 180 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$526
- AbbVie$354
- AstraZeneca$270
- Amgen$235
- Boehringer Ingelheim$159
- Johnson & Johnson$104
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,787100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $526 |
| AbbVie | 20 | $354 |
| AstraZeneca | 17 | $270 |
| Amgen | 16 | $235 |
| Boehringer Ingelheim | 9 | $159 |
| Johnson & Johnson | 8 | $104 |
| GSK | 6 | $101 |
| Pfizer | 6 | $94 |
| Astellas Pharma US Inc | 4 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $92 |
| Xeris Pharmaceuticals, Inc. | 3 | $88 |
| Exact Sciences | 5 | $85 |
| Lilly USA, LLC | 4 | $60 |
| Amarin Pharma, Inc. | 4 | $54 |
| Merck | 3 | $39 |
| Abbott | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Dexcom, Inc. | 2 | $32 |
| Gilead | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Nalpropion Pharmaceuticals LLC | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Noctrix Health, Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Abiomed | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Sonex Health, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Promius Pharma LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Antares Pharma, Inc. | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$2,787 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $112,768 |
| EliquisApixaban | 35 | $44,068 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $27,018 |
| Nurtec OdtRimegepant Sulfate | 14 | $25,258 |
| XareltoRivaroxaban | 19 | $25,001 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $23,110 |
| JardianceEmpagliflozin | 16 | $20,319 |
| MounjaroTirzepatide | 11 | $13,348 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $12,613 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $10,605 |
| Atorvastatin Calcium | 376 | $3,961 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $3,006 |
| SynthroidLevothyroxine Sodium | 23 | $3,003 |
| Rosuvastatin Calcium | 210 | $2,747 |
| Levothyroxine Sodium | 179 | $2,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $526 | $112,76872 claims |
| PfizerEliquis, Nurtec Odt | $94 | $69,32649 claims |
| MerckJanumet, Janumet Xr | $39 | $50,12846 claims |
| Johnson & JohnsonXarelto | $104 | $25,00119 claims |
| Boehringer IngelheimJardiance | $159 | $20,31916 claims |
| Lilly USA, LLCMounjaro | $60 | $13,34811 claims |
| GSKBreo Ellipta | $101 | $12,61319 claims |
| AbbVieSynthroid | $354 | $3,00323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Raleigh
- William CromwellRaleigh$2.7M
- Andrew DrabickRaleigh$289K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.